ClinicalTrials.gg
Not yet recruitingNCT07409051PersensPCUpdated Feb 13, 2026

Persistence of Sensitization to Contrast Media

An observational study in Contrast Media Allergy, sponsored by University Hospital, Montpellier. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by University Hospital, Montpellier · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Hypersensitivity by University Hospital, Montpellier — 3 open to participants now, 4 under way, none of them phase 3. Hypersensitivity · University Hospital, Montpellier.

Started
2026
with 2 others
Observational
8 of 12
1 open now
Registered
11th of 12
by date

Among the 12 studies in Hypersensitivity by University Hospital, Montpellier, this one is one of 3 that started in 2026, is one of 8 observational ones, and was the 11th registered.

Hypersensitivity

1,059 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

3 of the 12 studies in Hypersensitivity by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 38 (38%) set no upper age limit and 51 (50%) stop at 75 or younger; 55 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypersensitivity by University Hospital, Montpellier, or all of them as a file.
02

Study summary

The study aims to evaluate the persistence of IgE-mediated allergy to contrast media (CM) after a second exposure in patients who tested positive at both the first and second evaluations for CM allergy. It also aims to analyze the risk factors associated with the persistence of IgE-mediated sensitization after the second allergological assessment.

Read the detailed description

Drug allergy is often overdiagnosed, as only about 25% of cases labeled as allergic are confirmed. IgE-mediated drug allergy, responsible for immediate reactions up to anaphylaxis, carries inherent risks and relies primarily on in vivo testing, supplemented by in vitro assays in selected cases. In vivo assessment includes skin tests (ST), which, when positive, detect drug-specific IgE bound to mast cells, and drug provocation tests (DPT), which involve controlled re-exposure to the suspected drug.

When IgE-mediated allergy is confirmed, drugs with positive ST are strictly contraindicated for life. Drugs with negative ST are generally considered safe, and tolerance is often verified through DPT performed in specialized settings using stepwise dose escalation up to near-therapeutic doses. In some cases, drugs are reintroduced directly in real-life conditions without prior DPT.

Contrast media (CM) can trigger systemic reactions even at very low doses. In such cases, in vitro testing should ideally precede DPT to minimize systemic exposure. However, its use is limited by the small number of commercially available drug allergens, the need for specialized expertise for techniques such as the basophil activation test, and variable sensitivity depending on the drug, which remains largely unknown for CM. Skin testing for CM allergy has a very high negative predictive value (>95%), indicating that most patients with negative ST tolerate subsequent CM exposure. As a result, many centers do not systematically perform DPT after negative ST.

Evidence suggests that IgE-mediated drug allergy, including CM allergy, may decline over time, with conversion from positive to negative ST occurring after several years. However, it is unclear whether this reflects a true loss of clinical allergy, as documented re-exposures are rare and mostly anecdotal. Clinical experience shows that allergy may either resolve or persist despite negative follow-up tests.

Finally, the severity of drug-induced allergic reactions may be increased in patients with mast cell activation syndrome or mastocytosis, conditions characterized by elevated mast cell burden or reactivity and often suspected in the presence of elevated baseline serum tryptase levels.

03

Conditions studied

  • Contrast Media Allergy

Browse trials for

Keywords

  • IgE
  • Allergy
  • Contrast Media
  • Skin test
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Drug Allergy and Hypersensitivity Database of the Allergy Exploration Unit, Montpellier University Hospital (CHU Montpellier).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Adult patients (≥18 years) with confirmed IgE-mediated allergy to contrast media products after a first exposure.

Exclusion criteria

Exclusion Criteria:

  • Patients receiving H1 antihistamines for an allergic condition at the time of evaluation.
  • Patients with active eczema and/or uncontrolled asthma.
  • Pregnant or breastfeeding women, or women who have recently given birth.
  • Individuals under legal protection (e.g., guardianship).
  • Individuals deprived of liberty or involved in judicial proceedings.
  • Individuals without health insurance coverage.
  • Absence of clear, written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • IgE-dependent allergy to contrast media

    Skin testing using the prick method, involving gentle skin pricking at the site of allergen application, or intradermal testing (IDT) with 0.02-0.05 mL of allergenic solution will be performed in patients with a clinical history of hypersensitivity to contrast media. Baseline serum tryptase measured in blood samples will also be used as an indicator of hypersensitivity to contrast media, with values higher than 11 µg/L considered elevated.

    Diagnostic Test: Skin testing · Other: Baseline serum tryptase measurement

Interventions

  • Diagnostic testSkin testing

    Commercial contrast media will be used to perform skin prick testing or intradermal testing with 0.02-0.05 mL of allergenic solution. If not previously performed, a standard panel of prick tests with environmental allergens will be used to assess atopic status. Positive (histamine 10 mg/mL) and negative (saline) controls will be included. Skin testing will begin with prick tests, starting at the dilution that was positive during the initial evaluation. If negative, testing will proceed with intradermal injections using increasing concentrations until a positive response is observed. Once a positive result is obtained, skin testing for that contrast medium will be discontinued. A prick test will be considered positive if a wheal ≥3 mm with erythema and pruritus appears after 15 minutes. An intradermal test will be considered positive if a wheal ≥3 mm with erythema and pruritus appears after 20 minutes.

  • OtherBaseline serum tryptase measurement

    Seven milliliters of venous blood will be collected for baseline serum tryptase measurement.

06

What researchers measure

Primary outcomes

  1. Prevalence of IgE-mediated allergy to contrast media after the first exposure

    A skin prick test is considered positive if, after 15 minutes, a wheal measuring at least 3 mm appears, associated with erythema and pruritus. An intradermal test is considered positive if, after 20 minutes, a wheal measuring at least 3 mm appears, associated with erythema and pruritus

    Time frame: Inclusion

Secondary outcomes

  1. Risk factors of patients with IgE-mediated hypersensitivity to contrast media

    The presence of risk factors will be determined by analyzing the association between data extracted from the Drug Allergy and Hypersensitivity Database (DAHD) (i.e., sociodemographic characteristics, initial reaction to contrast media, results of the first allergy tests, and the presence of other allergic factors) and the persistence of reactivity to contrast media in patients with serum tryptase levels higher than 11 µg/L.

    Time frame: Inclusion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2028, 24 months later.

Of 102 non-industry observational studies under Hypersensitivity, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 203. This study's planned 24 months is below that.

Counting every sponsor, half of 125 studies reached it within 41 months; a quarter within 19 and three quarters within 136.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 13, 2026
StartEst.
Feb 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409051
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Feb 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Feb 13, 2026

Study contacts

Dr CHIRIAC
Contact
a-chiriac@chu-montpellier.fr
+33 04 67 33 61 07
Dr CHIRIAC
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion